The effect of concomitant treatment with SSRIs and statins: A population-based study

American Journal of Psychiatry

Volumn 173, Issue 8, 2016, Pages 807-815

  Köhler, Ole ^a   Gasse, Christiane ^a   Petersen, Liselotte ^a   Ingstrup, Katja G ^a   Nierenberg, Andrew A ^a   Mors, Ole ^a   Østergaard, Søren D ^a  

^a AARHUS UNIVERSITY HOSPITAL   (Denmark)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIHYPERTENSIVE AGENT; ANXIOLYTIC AGENT; ATORVASTATIN; BENZODIAZEPINE RECEPTOR STIMULATING AGENT; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CALCIUM CHANNEL BLOCKING AGENT; CARBAMAZEPINE; CITALOPRAM; DIURETIC AGENT; ESCITALOPRAM; FLUINDOSTATIN; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; LAMOTRIGINE; LITHIUM SALT; MEVINOLIN; OXCARBAZEPINE; PERIPHERAL VASODILATING AGENT; PRAVASTATIN; ROSUVASTATIN; SEROTONIN UPTAKE INHIBITOR; SERTRALINE; SIMVASTATIN; VALPROIC ACID;

ADOLESCENT; ADULT; AGE DISTRIBUTION; AGED; ANTIDEPRESSANT ACTIVITY; ARTICLE; CHARLSON COMORBIDITY INDEX; CHILD; CLINICAL PRACTICE; COHORT ANALYSIS; CONTROLLED STUDY; DENMARK; DEPRESSION; DRUG EFFICACY; DRUG SAFETY; FEMALE; FOLLOW UP; HUMAN; MAJOR CLINICAL STUDY; MALE; MORTALITY; POPULATION RESEARCH; PRIORITY JOURNAL; PROPENSITY SCORE; REGRESSION ANALYSIS; RENIN ANGIOTENSIN ALDOSTERONE SYSTEM; SUICIDAL BEHAVIOR; SUICIDE ATTEMPT; TREATMENT DURATION; TREATMENT RESPONSE; COMBINATION DRUG THERAPY; DEPRESSIVE DISORDER; DRUG POTENTIATION; HEALTH SURVEY; HOSPITAL ADMISSION; PROPORTIONAL HAZARDS MODEL; RISK; STATISTICS AND NUMERICAL DATA;

COHORT STUDIES; DENMARK; DEPRESSIVE DISORDER; DRUG SYNERGISM; DRUG THERAPY, COMBINATION; HUMANS; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; PATIENT ADMISSION; POPULATION SURVEILLANCE; PROPORTIONAL HAZARDS MODELS; RISK; SEROTONIN UPTAKE INHIBITORS;

EID: 84991272619     PISSN: 0002953X     EISSN: 15357228     Source Type: Journal    
DOI: 10.1176/appi.ajp.2016.15040463     Document Type: Article

References (36)

1. TrivediMH, Rush AJ, WisniewskiSR, et al:Evaluationofoutcomeswith citalopram for depression using measurement-based care in STARD: implications for clinical practice. Am J Psychiatry 2006; 163:28-40
2. Gaynes BN, Warden D, Trivedi MH, et al: What did STARD teach us? Resultsfrom a large-scale, practical, clinical trial for patients with depression. Psychiatr Serv 2009; 60:1439-1445
3. Nierenberg AA: Strategies for achieving full remission when firstline antidepressants are not enough. J Clin Psychiatry 2013; 74:e26
4. Müller N: Immunology of major depression. Neuroimmunomodulation 2014; 21:123-130
5. Benros ME, Waltoft BL, Nordentoft M, et al: Autoimmune diseases and severe infections as risk factors formooddisorders: a nationwide study. JAMA Psychiatry 2013; 70:812-820
6. Wium-Andersen MK, Ørsted DD, Nielsen SF, et al: Elevated C-reactive protein levels, psychological distress, and depression in 73, 131 individuals. JAMA Psychiatry 2013; 70:176-184
7. Abbasi SH, Hosseini F, ModabberniaA, et al: Effect of celecoxib addon treatment on symptoms and serum IL-6 concentrations in patients with major depressive disorder: randomized double-blind placebo-controlled study. J Affect Disord 2012; 141:308-314
8. Almeida OP, Flicker L, Yeap BB, et al: Aspirin decreases the risk of depression in older men with high plasma homocysteine. Transl Psychiatry 2012; 2:e151
9. Köhler O, Benros ME, Nordentoft M, et al: Effect of antiinflammatory treatment on depression, depressive symptoms, and adverse effects: a systematic review and meta-analysis of randomized clinical trials. JAMA Psychiatry 2014; 71:1381-1391
10. Weitz-Schmidt G: Statins as anti-inflammatory agents. Trends Pharmacol Sci 2002; 23:482-486
11. Zhang X, Norris SL, Gregg EW, et al: Depressive symptoms and mortalityamong persons with and without diabetes. AmJ Epidemiol 2005; 161:652-660
12. Mansi I, Frei CR, PughMJ, et al:Psychologic disorders and statin use: a propensity score-matched analysis. Pharmacotherapy 2013; 33:615-626
13. Parsaik AK, Singh B, Hassan Murad M, et al: Statins use and risk of depression: a systematic review and meta-analysis. J Affect Disord 2014; 160:62-67
14. Otte C, Zhao S, Whooley MA: Statin use and risk of depression in patients with coronary heart disease: longitudinal data from the Heart and Soul Study. J Clin Psychiatry 2012; 73:610-615
15. Young-Xu Y, Chan KA, Liao JK, et al: Long-term statin use and psychological well-being. J Am Coll Cardiol 2003; 42:690-697
16. Santos T, BaungratzMM, Haskel SP, et al: Behavioral interactions of simvastatin and fluoxetine in tests of anxiety and depression. Neuropsychiatr Dis Treat 2012; 8:413-422
17. Ghanizadeh A, Hedayati A: Augmentation of fluoxetine with lovastatin for treating major depressive disorder, a randomized doubleblind placebo controlled-clinical trial. Depress Anxiety 2013; 30: 1084-1088
18. Pedersen CB, Gøtzsche H, Møller JO, et al: The Danish Civil Registration System: a cohort of eight million persons. Dan Med Bull 2006; 53:441-449
19. Kildemoes HW, Sørensen HT, Hallas J: The Danish National Prescription Registry. Scand J Public Health 2011; 39(suppl): 38-41
20. Gardarsdottir H, Heerdink ER, Egberts AC: Potential bias in pharmacoepidemiological studies due to the length of the drug free period: a study on antidepressant drug use in adults in the Netherlands. Pharmacoepidemiol Drug Saf 2006; 15:338-343
21. Munk-Jørgensen P, Østergaard SD: Register-based studies of mental disorders. Scand J Public Health 2011; 39(suppl):170-174
22. Mors O, Perto GP, Mortensen PB: The Danish Psychiatric Central Research Register. Scand J Public Health 2011; 39(suppl):54-57
23. Köhler O, Petersen L, Mors O, et al: Inflammation and depression: combined use of selective serotonin reuptake inhibitors and NSAIDs or paracetamol and psychiatric outcomes. Brain Behav 2015; 5:e00338
24. Helweg-Larsen K: The Danish Register of Causes of Death. Scand J Public Health 2011; 39(suppl):26-29
25. Lynge E, Sandegaard JL, Rebolj M: The Danish National Patient Register. Scand J Public Health 2011; 39(suppl):30-33
26. Mortensen PB, Agerbo E, Erikson T, et al: Psychiatric illness and risk factors for suicide in Denmark. Lancet 2000; 355:9-12
27. Jensen VM, Rasmussen AW: Danish education registers. Scand J Public Health 2011; 39(suppl):91-94
28. Charlson ME, Pompei P, Ales KL, et al: A new method of classifying prognostic comorbidity in longitudinal studies: development and validation. J Chronic Dis 1987; 40:373-383
29. Nuttall M, van der Meulen J, EmbertonM: Charlson scores based on ICD-10 administrative data were valid in assessing comorbidity in patients undergoing urological cancer surgery. J Clin Epidemiol 2006; 59:265-273
30. Fine JP, Gray RJ: A proportional hazards model for the subdistribution of a competing risk. J Am Stat Assoc 1999; 94:496-509
31. Antons KA, Williams CD, Baker SK, et al: Clinical perspectives of statin-induced rhabdomyolysis. Am J Med 2006; 119:400-409
32. Andrade C: Selective serotonin reuptake inhibitor drug interactions in patients receiving statins. J Clin Psychiatry 2014; 75:e95-e99
33. Bellosta S, Corsini A: Statin drug interactions and related adverse reactions. Expert Opin Drug Saf 2012; 11:933-946
34. DeBerardis D, MariniS, PiersantiM, et al:Therelationships between cholesterol and suicide: an update. ISRN Psychiatry 2012; vol 2012, article ID 387901
35. Bock C, Bukh JD, Vinberg M, et al: Validity of the diagnosis of a single depressive episode in a case register. Clin Pract Epidemol Ment Health 2009; 5:4
36. Uggerby P, Østergaard SD, Røge R, et al: The validity of the schizophrenia diagnosis in theDanish PsychiatricCentralResearchRegister is good. Dan Med J 2013; 60:A4578